Table A2.13Posterior summaries (median with 95% credible interval) of hazard ratio (HR) for overall survival for sequences of treatment and probability that each sequence is best out of the 3 regimens of interest, assuming equivalence between the effect of capecitabine and 5-FU

HR > 1 favours the reference treatment.

Treatment sequenceHR (95% CrI)Prob best
Image app2fu5.jpg
FOLFOX/XELOX then FOLFIRI/XELIRI (reference)10.28
FOLFOX/XELOX then irinotecan0.96 (0.68, 1.37)0.39
FOLFIRI/XELIRI then FOLFOX/XELOX0.96 (0.74, 1.24)0.33

From: Appendix 2, Mixed treatment comparison and cost-effectiveness analysis for sequences of oxaliplatin and irinotecan-based chemotherapy in the treatment of advanced and metastatic colorectal cancer

Cover of Colorectal Cancer
Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer.
NICE Clinical Guidelines, No. 131.
National Collaborating Centre for Cancer (UK).
Copyright © 2011, National Collaborating Centre for Cancer.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.